The path to an RSV vaccine

Area of Science:

• Vaccinology
• Virology
• Pediatric Infectious Diseases

Background:

• Respiratory syncytial virus (RSV) represents a significant unmet need for infant vaccines globally.
• Despite over 40 years of research, a licensed human RSV vaccine is still unavailable.
• Severe RSV disease peaks in infants aged 2-3 months, highlighting the urgency for effective immunization strategies.

Purpose of the Study:

• To review the major challenges hindering the development of a safe and effective RSV vaccine for infants.
• To explore potential strategies and novel approaches to overcome existing obstacles in RSV vaccine research.
• To identify promising avenues for future RSV vaccine development, focusing on infant protection.

Main Methods:

• Review of historical RSV vaccine development efforts and associated challenges.
• Analysis of the immunological and virological factors complicating RSV vaccine design.
• Exploration of emerging technologies and immunization platforms for RSV vaccine candidates.

Main Results:

• Key challenges include the timing of severe disease in infants, antigen instability, vaccine-mediated disease enhancement, and inadequate animal models.
• Past vaccine trials have faced significant hurdles, including safety concerns and lack of efficacy.
• No RSV vaccine has yet been successfully licensed for human use, particularly for infants.

Conclusions:

• Maternal immunization offers a potential strategy to protect young infants.
• Structure-based antigen engineering and novel immunization platforms are promising for future RSV vaccines.
• Development of better animal models is crucial for accurately assessing RSV vaccine safety and efficacy.